European patent for Clovis' Rubraca upheld

The European Patent Office upheld a patent covering the crystalline formulation of Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS), confirming patent protection through 2031. The company has filed for a supplementary protection certificate that would extend protection under the patent through 2033.

Clovis reported $65 million in Rubraca sales for the first nine months of 2018. ...